On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption (IDE) approval for novel CBGM technology from FDA expected in Q4 2025 Rutherford, NJ, May …
Intel (NASDAQ:INTC) shares slid about 4% on Wednesday after Citi reported the company's processor market share fell to its lowest level since 2002, according to a research note. Warning! GuruFocus has detected 7 Warning Signs with INTC.Intel (INTC) Shares Tumble After Market Share Hits …
Aircraft leasing company FTAI Aviation (NASDAQ:FTAI) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 53.7% year on year to $502.1 million. Its non-GAAP profit of $1.02 per share was 16.3% above analysts’ consensus estimates. Is now the time to buy FTAI? …
(Reuters) -Canadian retailer Loblaw warned on Wednesday that prices increases will affect more products as U.S. President Donald Trump's tariffs put pressure on supply-chain costs for companies. As companies in categories such as packaged food and consumer goods raise prices, Loblaw said in March …
By Jamie McGeever ORLANDO, Florida (Reuters) - TRADING DAY Making sense of the forces driving global markets By Jamie McGeever, Markets Columnist Eyes turn to Powell The powerful rise in risk and growth assets lost some steam as U.S. stocks ended mixed and oil …
MISSISSAUGA, Ontario, May 14, 2025 (GLOBE NEWSWIRE) -- “Bird’s diversification and strategic focus on key market sectors has resulted in an economically resilient business that continues to drive both top line growth and margin accretion. Our extensive self-perform capabilities, focus on collaboration, and quality …
SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- On May 13, 2025, investors in UnitedHealth Group (NYSE: UNH) saw the price of their shares crater as much as $65.71 (-17%) after the company announced that its CEO Andrew Witty has stepped down and that …
–Data Demonstrated Statistically Significant Improvements in Primary and Secondary Endpoints with Most Subjects Achieving Near Normal Ranges of Wakefulness and Clinically Meaningful Improvements Across the Broad Range of Symptoms Investigated –Oveporexton Found to be Generally Safe and Well Tolerated –Phase 3 Readout of Oveporexton …
Stantec Highlights Record net revenue of $1.6 billion, an increase of 13.3% compared to Q1 2024 Adjusted EBITDA¹ increase of 19.1% to $252.3 million and adjusted EBITDA margin¹ of 16.2%, a 70 basis point increase over Q1 2024 Diluted EPS of $0.88 and adjusted …
Analyzing the Latest 13F Filing for Strategic Insights Robert Bruce (Trades, Portfolio) recently submitted the 13F filing for the first quarter of 2025, providing insights into his investment moves during this period. Robert Bruce (Trades, Portfolio) is the founder of Bruce & Co, the …